Clinical trial · Interventional
Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors
NCT07019259CI-TRIAL-00114641recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Chemotherapy-induced Peripheral Neuropathy | — | UNRESOLVED | — |
| Childhood Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anodyne Therapy System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Light Therapy
- description
- Week 1 will include a baseline evaluation in clinic. In weeks 1-6, participants will complete 18 total light therapy sessions (3 sessions/week, 15/minutes session). The first session will be observed in clinic at the time of the baseline evaluation, and the remaining 17 sessions will be completed at home. In Week 7 survivors will follow-up in clinic for a repeat evaluation with the physical therapist (or study team member). .
- interventionNames
- Device: Anodyne Therapy System
Primary outcomes (1)
- measure
- Feasibility of light therapy protocol
- timeFrame
- 7 weeks
- description
- Measured as proportion of participants adhering to protocol (completing 12 of 18 sessions), with ≥70% of participants adhering to the protocol indicating feasibility
Secondary outcomes (4)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Years
Show eligibility criteria text
Inclusion Criteria: * History of childhood cancer (\<21 years of age at diagnosis) * Current age five years or older (due to availability of validated measures for CIPN in this age group) * History of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN * CIPN as assessed by a trained physical therapist defined as a score of four or higher on the ped-mTNS (for survivors \<18 years old at evaluation), or the mTNS (for survivors 18 years or older at evaluation) Exclusion Criteria: * Currently Pregnant or lactating (by patient report, at initiation or at any point of the study) * Inability to sit still for at least 15 minutes * Diagnosis of neuropathy prior to cancer treatment * Active cancer diagnosis or cancerous skin lesion * Central nervous system tumor (due to lack of validated measures for CIPN in this population) * Cancer lesion or open wound in the area to be treated, or any condition that can potentially be made worse by the correct or incorrect use of the device.
References
Publications (0)
Data not yet available
No reference posted for this study.